TMC appoints new CCO and strengthens senior team with four appointments and Non-Executive Director

TMC Pharma Services (TMC), the global organisation supporting and enabling Pharma/Biotech companies to develop innovative treatments for rare diseases and oncology, has further strengthened its team with a raft of senior hires as it continues to grow internationally.

Stewart Sharpe joins TMC as Chief Commercial Officer, with responsibility for overseeing the company’s continued UK and international success, with a number of new strategic relationships developed in North America, Asia, EU and the Middle East, as well as in the UK. Stewart is an enthusiastic business leader with a successful track record leading pharma organisations, building teams and launching pharma brands worldwide.  He brings extensive experience to the role, having previously been VP Global Commercial Lead at Syneos Health, where he led and developed client-focused, fully integrated solutions for every stage of product development and commercialisation.

Alongside Stewart, Rondeep (Ronnie) Bhui has been appointed as Head of Strategic Planning, joining from Boehringer Ingelheim Vetmedica GmbH where he was Head of Global Pharmacovigilance. A seasoned pharmaceutical professional, Ronnie has considerable experience in Human and Veterinary Medicines developing strategic transformation solutions in the areas of Pharmacovigilance, Regulatory and Clinical Research.

TMC has also welcomed Dr Victoria Datsenko as VP Clinical Services, together with Dr Marcelo Vaz as Head of Medical Services.  Bringing more than 20 years’ development experience within global clinical research, Victoria’s expertise covers all clinical trial phases across a broad range of therapies, with particular strength in oncology, cell and gene therapy. Marcelo was previously head of the respiratory group at the Biotech unit at ICON plc, where he developed clinical research expertise across a range of respiratory diseases, including COPD, asthma and lung cancer.

Successfully attracting these four seasoned and talented industry executives to TMC’s senior team (2 for entirely new roles) is another milestone development in TMC’s growth since it secured an £18m minority investment from private equity firm LDC last year.  Seeking to capitalise on the positive market dynamics, TMC has already strengthened its leadership team with the appointment of biotech industry veteran Gordon Cameron as a Non-Executive Director (Oct-22) and also by increasing its headcount by >20% since LDC’s investment.

With its UK headquarters in Hampshire and subsidiaries in the EU and Japan, TMC works predominantly with clients in North America, EU and Asia, and is unique in providing comprehensive medicinal product development support, from pre-clinical to post-marketing, for human medicines and devices, including all strategic and hands-on activities.  With over 23 years of experience, TMC specialises in product development for rare/orphan diseases and oncology. TMC’s mature and exceptionally experienced team on-the-ground provide regulatory, medical, clinical and pharmacovigilance needs around the world.

Julie Matthews, Chief Executive Officer at TMC, said: “We’re thrilled to be welcoming so many experienced and well-respected healthcare professionals to our team. They each have wide-ranging experience of growing businesses on an international scale and, as we continue to pursue expansion in the USA, Asia and other key global territories, they will be a huge asset in helping us to achieve our goals.”